Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes.
作者信息
Son Jang Won
机构信息
Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.
出版信息
Endocrinol Metab (Seoul). 2021 Feb;36(1):57-59. doi: 10.3803/EnM.2021.109. Epub 2021 Feb 24.
Abstract
摘要
相似文献
1
Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes.解锁胰高血糖素样肽-1类似物与成纤维细胞生长因子21联合用药对2型糖尿病动脉粥样硬化发病机制的治疗潜力。
Endocrinol Metab (Seoul). 2021 Feb;36(1):57-59. doi: 10.3803/EnM.2021.109. Epub 2021 Feb 24.
2
Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model.胰高血糖素样肽-1 类似物和成纤维细胞生长因子 21 联合对 2 型糖尿病小鼠模型中动脉粥样硬化相关过程的影响。
Endocrinol Metab (Seoul). 2021 Feb;36(1):157-170. doi: 10.3803/EnM.2020.781. Epub 2021 Feb 24.
3
Does GLP-1 suppress hepatocyte glucose production directly, via fibroblast growth factor 21?胰高血糖素样肽-1是否通过成纤维细胞生长因子21直接抑制肝细胞葡萄糖生成？
EBioMedicine. 2019 Mar;41:5-6. doi: 10.1016/j.ebiom.2019.03.012. Epub 2019 Mar 12.
4
Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus.利拉鲁肽治疗对2型糖尿病患者氧化应激和心钠素水平的影响。
Endocrine. 2014 Dec;47(3):962-4. doi: 10.1007/s12020-014-0246-6. Epub 2014 Apr 3.
5
Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.胰高血糖素样肽-1（GLP-1）与人类不变自然杀伤 T 细胞的调控：肥胖、糖尿病和银屑病的启示。
Diabetologia. 2011 Nov;54(11):2745-54. doi: 10.1007/s00125-011-2232-3. Epub 2011 Jul 9.
6
Liraglutide therapy in Prader-Willi syndrome.利拉鲁肽治疗普拉德-威利综合征
Diabet Med. 2011 Jun;28(6):755-6. doi: 10.1111/j.1464-5491.2011.03280.x.
7
Incretins: what does the future hold?肠促胰岛素：未来前景如何？
Diabetes Technol Ther. 2005 Oct;7(5):809-12. doi: 10.1089/dia.2005.7.809.
8
Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.利拉鲁肽治疗肥胖的2型糖尿病患者——一家体重管理中心的经验
Eur J Intern Med. 2014 Mar;25(3):e38-9. doi: 10.1016/j.ejim.2013.12.009. Epub 2014 Jan 10.
9
Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat.塔斯格鲁肽，一种新型人胰高血糖素样肽-1 类似物，可改善 Zucker 糖尿病肥胖大鼠的葡萄糖稳态和体重。
Diabetes Obes Metab. 2010 Aug;12(8):674-82. doi: 10.1111/j.1463-1326.2010.01207.x.
10
[Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].[2型糖尿病的血糖控制之外。胰高血糖素样肽-1受体激动剂治疗的前景与风险]
G Ital Cardiol (Rome). 2011 Dec;12(12 Suppl 2):3-4. doi: 10.1714/985.10683.
本文引用的文献
1
Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model.胰高血糖素样肽-1 类似物和成纤维细胞生长因子 21 联合对 2 型糖尿病小鼠模型中动脉粥样硬化相关过程的影响。
Endocrinol Metab (Seoul). 2021 Feb;36(1):157-170. doi: 10.3803/EnM.2020.781. Epub 2021 Feb 24.
2
A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis.一种新型 GLP-1 和 FGF21 双重激动剂具有治疗糖尿病和非酒精性脂肪性肝炎的潜力。
EBioMedicine. 2021 Jan;63:103202. doi: 10.1016/j.ebiom.2020.103202. Epub 2021 Jan 7.
3
Effect of Fibroblast Growth Factor 21 on the Development of Atheromatous Plaque and Lipid Metabolic Profiles in an Atherosclerosis-Prone Mouse Model.成纤维细胞生长因子 21 对动脉粥样硬化易损小鼠模型动脉粥样硬化斑块形成和脂代谢特征的影响。
Int J Mol Sci. 2020 Sep 17;21(18):6836. doi: 10.3390/ijms21186836.
4
Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia.长效 GLP-1 和 FGF21 双重激动剂从可注射储库中的释放可保护小鼠免受肥胖和高血糖的影响。
Sci Adv. 2020 Aug 26;6(35):eaaz9890. doi: 10.1126/sciadv.aaz9890. eCollection 2020 Aug.
5
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic.成纤维细胞生长因子 21 在代谢性疾病中的治疗潜力：从实验室到临床。
Nat Rev Endocrinol. 2020 Nov;16(11):654-667. doi: 10.1038/s41574-020-0386-0. Epub 2020 Aug 6.
6
Going Back to the Biology of FGF21: New Insights.回到 FGF21 的生物学：新的见解。
Trends Endocrinol Metab. 2019 Aug;30(8):491-504. doi: 10.1016/j.tem.2019.05.007. Epub 2019 Jun 24.
7
Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output.肝源成纤维细胞生长因子 21 介导胰高血糖素样肽-1 减轻肝葡萄糖输出的作用。
EBioMedicine. 2019 Mar;41:73-84. doi: 10.1016/j.ebiom.2019.02.037. Epub 2019 Mar 1.
8
A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21.十二年的探索：成纤维细胞生长因子 21 的生理学和药理学研究进展
Cell Metab. 2019 Feb 5;29(2):246-253. doi: 10.1016/j.cmet.2019.01.004.
9
FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms.成纤维细胞生长因子21通过脂肪依赖和非依赖机制调节新陈代谢。
Cell Metab. 2017 Apr 4;25(4):935-944.e4. doi: 10.1016/j.cmet.2017.03.005.
10
iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy.iNKT细胞诱导成纤维细胞生长因子21进行产热，且在胰高血糖素样肽1治疗中实现最大程度体重减轻时是必需的。
Cell Metab. 2016 Sep 13;24(3):510-519. doi: 10.1016/j.cmet.2016.08.003. Epub 2016 Sep 1.
Zotero 插件